Psychosis in a Military Veteran in the Context of Hallucinogen Use: A Case Report DOI Open Access

Paria Parhami,

Sydney E Moriarty,

Jay R. Parikh

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 19, 2025

N, N-dimethyltryptamine (DMT) is a potent hallucinogenic compound with increasing recreational use despite limited safety data. While DMT has been linked to psychosis, delusional parasitosis as specific manifestation remains unreported. We present novel case of 60-year-old female veteran chronic post-traumatic stress disorder (PTSD), history major depressive disorder, past marijuana use, and no prior psychiatric hospitalizations, who developed persistent delusions parasitic infestation following prolonged intravenous (IV) DMT. She was referred acute inpatient psychiatry by the residential PTSD program in same hospital system, where she expressed upon intake there strong conviction that worms were coming out her skin. Upon admission psychiatry, patient presented severe anxiety about minor appearing skin excoriations. These likely result consequent precipitator delusion parasite-infected eight months ago during plumbing leak home. A review records revealed endorsement these symptoms multiple providers over months. also reported using IV at home 1-2 times per month for 18 As timing hallucinogen development psychotic not fully consistent, concern primary exacerbated substance use. Her persisted initial haloperidol treatment initiated hospitalization but improved after 15 days hospitalization, clearance psychoeducation. This suggests potential link between parasitosis, published studies have specifically explored this association, highlighting need further research, particularly repeated administration.

Language: Английский

Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis DOI

Yuan Yao,

Dan Guo,

Tangsheng Lu

et al.

Psychiatry Research, Journal Year: 2024, Volume and Issue: 335, P. 115886 - 115886

Published: March 28, 2024

Language: Английский

Citations

30
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile DOI Creative Commons
Friederike Holze, Nirmal Singh, Matthias E. Liechti

et al.

Biological Psychiatry Cognitive Neuroscience and Neuroimaging, Journal Year: 2024, Volume and Issue: 9(5), P. 472 - 489

Published: Feb. 1, 2024

Psychedelic compounds, including psilocybin, LSD, DMT, and 5-MeO-DMT all of which are serotonin (5-HT) 2A receptor agonists being investigated as potential treatments. This review aims to summarize the current clinical research on these four compounds mescaline guide future research. Their mechanism/s action, pharmacokinetics, pharmacodynamics, efficacy, safety were reviewed. While evidence for therapeutic indications, with exception psilocybin depression, is still relatively scarce, we noted no differences in psychedelic effects beyond effect duration. It remains therefore unclear whether different profiles contribute compounds. More needed differentiate order inform might be best uses.

Language: Английский

Citations

21
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects DOI Creative Commons
Helena D. Aicher, Michael J. Mueller, Dario A. Dornbierer

et al.

Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 8, 2024

There is growing scientific evidence for the therapeutic benefits of Amazonian plant-based psychedelic "ayahuasca" neuropsychiatric disorders such as depression and anxiety. However, there are certain challenges when incorporating botanical ayahuasca into biomedical research clinical therapy environments. Formulations inspired by ayahuasca, which contain specific standardized active components, a potential remedy.

Language: Английский

Citations

17
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression DOI
Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason

et al.

American Journal of Psychiatry, Journal Year: 2025, Volume and Issue: 182(1), P. 33 - 46

Published: Jan. 1, 2025

Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with expectation that these can produce effects following an intense but brief psychedelic intervention. The current paper reviews clinical pharmacology 5-MeO-DMT DMT their potential benefits challenges treatment depression. Both compounds display affinities for variety monoamine receptors transporters, mostly so serotonergic (5HT) receptors, including 5HT

Language: Английский

Citations

4
Exploring DMT: Endogenous Role and Therapeutic Potential DOI Creative Commons
J. Schimmelpfennig, Kamila Jankowiak-Siuda

Neuropharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 110314 - 110314

Published: Jan. 1, 2025

Language: Английский

Citations

2
Effects of DMT on mental health outcomes in healthy volunteers DOI Creative Commons
Christopher Timmermann, Richard J. Zeifman, David Erritzøe

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Feb. 7, 2024

Abstract Psilocybin, a serotonergic psychedelic, is being increasingly researched in clinical studies for the treatment of psychiatric disorders. The relatively lengthy duration oral psilocybin’s acute effects (4–6 h) may have pragmatic and cost-effectiveness limitations. Here, we explored intravenous (IV) N,N-Dimethyltryptamine (DMT), closely related, but faster-acting psychedelic intervention, on mental health outcomes healthy volunteers. Data reported from two separate analyses: (1) A comparison health-related variables 1 week after 7, 14, 18, 20 mg IV DMT versus saline placebo (n = 13) and, (2) prospective dataset assessing before 2 weeks 17). Mental included measures depression severity (QIDS-SR16), trait anxiety (STAI-T), Neuroticism (NEO-FFI), wellbeing (WHO-5), meaning life (MLQ), optimism (LOT-R), gratitude (GQ-6). In both placebo-controlled datasets, significant improvements scores were found 1–2 administration. Significant reductions only sample. Finally, changes correlated with peak experiences (assessed via ‘Oceanic Boundlessness’). While use cohorts pooled analysis limits generalizability these correlational findings, results suggest that reduce depressive symptomatology by inducing experiences. short half-life its potential flexible dosing controlled infusions makes it an appealing candidate medicine. Further research samples needed to corroborate therapeutic DMT.

Language: Английский

Citations

15
In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin DOI Creative Commons
Jan Thomann, Karolina E. Kolaczynska,

Oliver V Stoeckmann

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: April 29, 2024

In vivo , psilocybin is rapidly dephosphorylated to psilocin which induces psychedelic effects by interacting with the 5-HT 2A receptor. Psilocin primarily undergoes glucuronidation or conversion 4-hydroxyindole-3-acetic acid (4-HIAA). Herein, we investigated psilocybin’s metabolic pathways in vitro and conducting a thorough analysis of enzymes involved. Metabolism studies were performed using human liver microsomes (HLM), cytochrome P450 (CYP) enzymes, monoamine oxidase (MAO), UDP-glucuronosyltransferase (UGT). metabolism was examined male C57BL/6J mice plasma samples. Approximately 29% metabolized HLM, while recombinant CYP2D6 CYP3A4 nearly 100% 40% psilocin, respectively. Notably, 4-HIAA 4-hydroxytryptophol (4-HTP) detected HLM but not CYPs. MAO-A transformed into minimal amounts 4-HTP. 4-HTP only present . Neither nor showed relevant interactions at assessed receptors. contrast data, UGT1A10 did extensively metabolize Furthermore, two putative metabolites observed. N -methyl-4-hydroxytryptamine (norpsilocin) identified (CYP2D6) mice, an oxidized metabolite humans. However, genotype influence concentrations study population. conclusion, MAO-A, CYP2D6, are involved psilocin’s metabolism. The discovery norpsilocin humans further unravels Despite limitations replicating phase II these findings hold significance for studying drug-drug advancing research on as therapeutic agent.

Language: Английский

Citations

15
The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis DOI
Arman Shafiee, Razman Arabzadeh Bahri, M. Rafiei

et al.

Journal of Psychopharmacology, Journal Year: 2024, Volume and Issue: 38(5), P. 425 - 431

Published: Feb. 22, 2024

Background: Recent interest in the potential therapeutic effects of psychedelics has led to investigations into their influence on molecular signaling pathways within brain. Aims: Integrated review and analysis different studies this field. Methods: A systematic search was conducted across international databases including Embase, Scopus, Web Science, PubMed from inception 9 July 2023. Eligibility criteria encompassed published peer-reviewed evaluating changes brain-derived neurotrophic factor (BDNF) levels after psychedelic consumption. Outcomes: total nine were included our study. The meta-analysis demonstrated significantly higher BDNF consumers compared healthy controls, with a pooled standardized mean difference 0.26 (95% CI: 0.10–0.42, I 2 = 38.51%, p < 0.001). Leave-one-out indicated robustness results upon removal individual psychedelics. No significant publication bias observed. highlight neuroplasticity by altering levels. Conclusions: More precisely, documented rise indicates neurobiological mechanism which could enhance synaptic plasticity foster growth neurons. Given limited data available topic, conclusions remain uncertain. Consequently, we highly recommend additional research more extensive sample sizes yield reliable evidence

Language: Английский

Citations

9
Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis DOI Creative Commons
Katelijne V. van der Heijden, Marije E. Otto, Jan W. Schoones

et al.

Clinical Pharmacokinetics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 21, 2025

N,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of pharmacokinetics (PK) essential to determine appropriate dose ranges future clinical studies. We conducted a systematic literature review on the PK DMT. Clinical studies that administered known amounts DMT and reported data and/or parameters humans were included. Additionally, raw requested from authors extracted publications. In total, 219 references retrieved, which 13 publications included, covering eight distinct datasets. All intravenously infusion schemes, except one intramuscular administration. High variability dose-normalized exposure differences bolus versus administration observed. extensively redistributed other tissues, based biphasic elimination profile high volume distribution terminal phase (range 123–1084 L). It eliminated rapidly, with half-life 4.8–19.0 min clearance 8.1–46.8 L/min. This result rapid metabolization indole-3-acetic acid (IAA), also reflected fact time maximum concentration IAA similar demonstrates have been characterized limited extent, lack details regards demographics, absolute doses, parameters. Additional are necessary investigate intersubject following or prolonged infusion. Addressing these issues development as pharmacotherapeutic neuropsychiatry.

Language: Английский

Citations

1
Cardiovascular safety of psychedelic medicine: current status and future directions DOI Creative Commons
Agnieszka Wsół

Pharmacological Reports, Journal Year: 2023, Volume and Issue: 75(6), P. 1362 - 1380

Published: Oct. 24, 2023

Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychiatric diseases was known before their prohibition. An increasing number recent studies, due to indisputable resurgence serotonergic hallucinogens, have shown efficacy alleviating depression, anxiety, substance abuse therapies, existential distress patients facing life-threatening illness. generally considered be physiologically safe with low toxicity addictive potential. However, agonism at receptors should context possible serotonin-related cardiotoxicity (5-HT2A/2B 5-HT4 receptors), influence on platelet aggregation (5-HT2A receptor), proarrhythmic The use psychedelics has also been associated significant sympathomimetic effects both experimental clinical studies. Therefore, present review aims provide a critical discussion cardiovascular safety psilocybin, d-lysergic acid diethylamide (LSD), N,N-dimethyltryptamine, ayahuasca, mescaline, based results research trials humans. Experimental studies inconsistent information potential psychedelics. Data from point relative psychedelic-assisted therapies population “healthy” volunteers. there is insufficient evidence carried out microdoses psychedelics, still lack data disease. exact determination psychedelic (especially long-term therapies) requires further research.

Language: Английский

Citations

21